Tyme Technologies, Inc.
(NASDAQ : TYME)

( )
TYME PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-0.36%145.380.6%$1129.21m
MRKMerck & Co., Inc.
-2.12%76.710.6%$1006.42m
PFEPfizer Inc.
-2.35%43.930.9%$997.18m
ABBVAbbVie, Inc.
-3.75%86.942.2%$612.33m
LLYEli Lilly and Company
-1.95%113.581.0%$522.64m
BMYBristol-Myers Squibb Company
-0.32%53.081.4%$462.56m
NVSNovartis AG Sponsored ADR
-2.24%87.060.2%$235.59m
AZNAstraZeneca PLC Sponsored ADR
-1.78%38.181.3%$201.57m
GSKGlaxoSmithKline plc Sponsored ADR
-0.37%37.280.2%$135.92m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.57%45.380.1%$62.68m
SNYSanofi Sponsored ADR
-0.55%43.470.2%$42.50m
LCILannett Company, Inc.
-1.65%5.3737.0%$12.19m
AKTXAkari Therapeutics Plc Sponsored ADR
1.11%1.821.7%$0.03m
EPIXESSA Pharma Inc
-13.07%2.300.1%$0.00m

Company Profile

Tyme Technologies, Inc. operates as a clinical-stage biopharmaceutical company focused on development and commercialization of highly targeted cancer therapeutics with a broad range of oncology indications. Its clinical program, SM-88 is a novel combination therapy based on dysfunctional metyrosine derivatives and has shown complete or partial imaging responses in 15 different cancer subtypes, including solid tumors, sarcomas, gliomas and hematological malignancies, without demonstrating drug-related severe adverse events. The company was founded on November 22, 2011 and is headquartered in New York, NY.